WO/2016/075513 SUCTIONING DEVICE FOR LARGE ARTIFICIAL WATER BODIES||WO||19.05.2016|
||PCT/IB2014/065981||CRYSTAL LAGOONS (CURACAO) B.V.||FISCHMANN TORRES, Fernando Benjamin|
The present invention relates to a flexible suctioning device for suctioning floes from the bottom of large artificial water bodies with surfaces larger than 10,000 m and with bottoms covered with plastic liners that do not have centralized filtration systems, and that is able to clean a bottom surface of large artificial water bodies at a surface cleaning rate of 325,000 ft 2 per 24 hours (30,000 m2 per 24 hours) or more, where the bottom surface of the large artificial water bodies can be irregular and sloped, and where the suctioning device is reversible and is supported by a plurality of brushes, comprising first brushes, disposed to provide appropriate support to the suction device and minimize the dispersion and re-suspension of settled floes. The suctioning device is designed in order to concentrate the suction power in a series of suction points, where the suctioning device is connected to an external filtration system that may not be attached to the suctioning device.
WO/2015/134839 P-SUBSTITUTED ASYMMETRIC UREAS AND MEDICAL USES THEREOF||WO||11.09.2015|
||PCT/US2015/019112||HELSINN HEALTHCARE SA||GIULIANO, Claudio|
Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor. The compounds have the general Formula (I): or pharmaceutically acceptable salts thereof.
WO/2015/124576 2-AMINO-3, 5, 5-TRIFLUORO-3, 4, 5, 6-TETRAHYDROPYRIDINES AS BACE1 INHIBITORS FOR TREATMENT OF ALZHEIMER'S DISEASE||WO||27.08.2015|
||PCT/EP2015/053327||H. LUNDBECK A/S||JUHL, Karsten|
The present invention is directed to novel inhibitors of the BACE1 enzyme. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders for which the reduction of Αβ deposits is beneficial such as Alzheimer's disease.
WO/2015/124586 TOPICAL ANTIFUNGAL COMPOSITION FOR TREATING ONYCHOMYCOSIS||WO||27.08.2015|
||PCT/EP2015/053352||POLICHEM SA||MAILLAND, Federico|
The present invention is directed to a nail lacquer consisting essentially of ciclopirox as an antimycotic agent, hydroxypropyl chitosan as film forming agent, water and a lower alkanol as solvent. The invention is also directed to such a nail lacquer for use in treating onychomycosis.
WO/2015/124610 COOLED STORAGE SYSTEM||WO||27.08.2015|
||PCT/EP2015/053390||JAKOB HATTELAND LOGISTICS AS||HOGNALAND, Ingvar|
A cooled storage system comprises a grid structure (20) of storage cells, where each cell is arranged to accommodate a vertical stack of storage bins and having a top level, at least one remotely operated vehicle (27) arranged to move at the top level of the grid structure (20) and receive a bin from a storage cell at the top level of the grid structure (20), where there is provided thermal insulation between at least a section of the grid structure (20) and the remotely operated vehicle (27), and said section of the grid structure (20) has a temperature that is lower than the temperature of the remotely operated vehicle (27).
WO/2015/124852 ROAD-WIDENING STRUCTURE||WO||27.08.2015|
||PCT/FR2015/050358||TECHNOLOGIE ALPINE DE SECURITE -TAS||BOUTILLIER, Benoît|
The invention relates to a road-widening structure (1) comprising : a first part (10) for applying to a support used to support a first portion of the road, and a second part arranged as a cantilever, secured to the first part by a side wall (18, 25) and designed to support a second portion of the road.
WO/2015/120563 METHOD AND DEVICE FOR CLEANING INTERIORS OF CONTAINERS AND SYSTEMS||WO||20.08.2015|
||PCT/CH2015/000011||BANG & CLEAN GMBH||BÜRGIN, Markus|
The invention relates to a method and a cleaning device (1, 101) for removing deposits from interiors (54) of containers and systems (51) by means of explosive technology. The cleaning device (1, 101) contains a cleaning appliance (2, 102) having a receiving space (11, 111) and at least one pressure container (21, 21'; 121, 121') connected to the cleaning appliance (2, 102) via at least one metering fitting (18, 18'; 118, 118'). The introduction of the at least one gaseous component into the cleaning appliance (2, 102) is controlled in accordance with the principle of the pressure difference between a maximum pressure at the start of the introduction and a desired residual pressure following completion of the introduction. To this end, the desired residual pressure in the pressure container (21, 21'; 121, 121') is defined on the basis of the quantity of gaseous component to be introduced, starting from the maximum pressure, and the introduction of the at least one gaseous component is stopped when the desired residual pressure is achieved. The desired residual pressure is in this case in the positive pressure range.
WO/2015/123533 PYRAZINES MODULATORS OF GPR6||WO||20.08.2015|
||PCT/US2015/015841||TAKEDA PHARMACEUTICAL COMPANY LIMITED||ADAMS, Mark E.|
The present invention provides compounds of formula (I): which are useful as modulators of GPR6, pharmaceutical compositions thereof, methods for treatment of conditions associated with GPR6, processes for making the compounds and intermediates thereof.
WO/2015/118097 HEXAHYDROFUROPYRROLES AS PDE1 INHIBITORS||WO||13.08.2015|
||PCT/EP2015/052492||H. LUNDBECK A/S||KEHLER, Jan|
The present invention provides hexahydrofuropyrroles as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
WO/2015/107495 N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2||WO||23.07.2015|
||PCT/IB2015/050345||NOVARTIS AG||CHEN, Christine Hiu-tung|
The present invention relates to compounds of formula I: in which p, q, Y1, Y2, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b, R7 and R8 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.